Cardiff Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Cardiff Oncology
CRDF Stock  USD 1.75  0.13  8.02%   
Cardiff Oncology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cardiff Oncology's valuation are provided below:
Gross Profit
-39.5 M
Market Capitalization
109.1 M
Enterprise Value Revenue
149.9803
Revenue
501 K
Earnings Share
(0.79)
There are over one hundred nineteen available fundamental signals for Cardiff Oncology, which can be analyzed over time and compared to other ratios. Active traders should verify all of Cardiff Oncology prevailing fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. The current Market Cap is estimated to decrease to about 66.7 M. Enterprise Value is estimated to decrease to about 51.8 M

Cardiff Oncology Total Revenue

430,804

Check Cardiff Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cardiff Oncology's main balance sheet or income statement drivers, such as Selling General Administrative of 7.9 M, Other Operating Expenses of 59.6 M or Research Development of 44.5 M, as well as many indicators such as Price To Sales Ratio of 204, Dividend Yield of 0.0058 or PTB Ratio of 2.72. Cardiff financial statements analysis is a perfect complement when working with Cardiff Oncology Valuation or Volatility modules.
  
Build AI portfolio with Cardiff Stock
Check out the analysis of Cardiff Oncology Correlation against competitors.
For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.

Cardiff Oncology Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding57.5 M54.8 M19.6 M
Slightly volatile
Common Stock6 K6.3 K309.1 K
Slightly volatile
Short and Long Term Debt Total1.3 M1.4 M4.1 M
Pretty Stable
Other Current Liabilities9.5 M9.1 M3.9 M
Slightly volatile
Total Current Liabilities16.2 M15.4 M6.8 M
Slightly volatile
Property Plant And Equipment Net1.8 M2.4 M1.8 M
Slightly volatile
Accounts Payable5.8 M5.5 M1.9 M
Slightly volatile
Non Current Assets Total2.3 M2.5 M2.3 M
Slightly volatile
Non Currrent Assets Other75.4 K79.3 K452.6 K
Very volatile
Net Receivables933.4 K889 K328.8 K
Slightly volatile
Non Current Liabilities Total695.1 K731.7 K4.6 M
Slightly volatile
Other Current Assets1.6 M2.9 M1.6 M
Slightly volatile
Total Liabilities11.4 M16.4 M11.1 M
Pretty Stable
Property Plant And Equipment Gross7.5 M7.1 M2.9 M
Slightly volatile
Short Term Debt1.2 M639 K1.2 M
Pretty Stable
Common Stock Total Equity4.7 K4.6 K4.3 K
Pretty Stable
Net Tangible Assets128.4 M122.3 M60 M
Slightly volatile
Long Term Debt Total10.7 M16.3 M10.6 M
Slightly volatile
Capital Surpluse249.6 M465.6 M238.6 M
Slightly volatile
Deferred Long Term Liabilities243.7 K256.5 K1.8 M
Slightly volatile
Preferred Stock Total Equity1.2 K1.1 K451
Slightly volatile
Property Plant Equipment1.2 M1.1 M1.3 M
Very volatile
Other Assets0.860.9358.7 K
Pretty Stable
Long Term Debt14 M16.3 M13.3 M
Slightly volatile
Other Liabilities377.3 K397.1 K1.3 M
Slightly volatile
Short and Long Term Debt1.5 M1.2 M1.8 M
Slightly volatile
Net Invested Capital76 M95.4 M45.8 M
Slightly volatile
Net Working Capital74.4 M93.9 M44 M
Slightly volatile
Capital Stock4.6 K6.3 K6.7 K
Slightly volatile
Capital Lease Obligations2.2 M1.8 M1.9 M
Slightly volatile
Non Current Liabilities Other1.6 M2.3 M1.3 M
Slightly volatile

Cardiff Oncology Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative7.9 M14.4 M8.5 M
Slightly volatile
Other Operating Expenses59.6 M56.7 M27 M
Slightly volatile
Research Development44.5 M42.4 M16.4 M
Slightly volatile
Total Operating Expenses59.6 M56.7 M26.7 M
Slightly volatile
Depreciation And Amortization423.5 K464.6 K414.1 K
Slightly volatile
Total Revenue430.8 K785.5 K424.5 K
Slightly volatile
Selling And Marketing Expenses434.8 K457.7 K1.7 M
Pretty Stable
Cost Of Revenue441.4 K464.6 K2.3 M
Very volatile
Preferred Stock And Other Adjustments19.8 K21.6 K25 K
Slightly volatile
Interest Income3.9 M3.7 M1.9 M
Slightly volatile
Reconciled Depreciation453.9 K363.6 K828.8 K
Slightly volatile
Non Recurring531.7 K598.2 K653 K
Slightly volatile

Cardiff Oncology Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.1 M5.5 M3.2 M
Slightly volatile
Begin Period Cash Flow23.6 M24.9 M24 M
Pretty Stable
Depreciation420.9 K464.6 K431.3 K
Slightly volatile
Dividends Paid354 K372.6 K14.1 M
Slightly volatile
End Period Cash Flow62.2 M59.2 M31.4 M
Slightly volatile
Sale Purchase Of Stock64.1 K67.5 K20.6 M
Slightly volatile
Change To Netincome2.4 M3.8 M3.1 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio204272263
Pretty Stable
Dividend Yield0.00580.00610.6353
Very volatile
Days Sales Outstanding390372247
Slightly volatile
Average Payables520.2 K977.1 K892.3 K
Slightly volatile
Stock Based Compensation To Revenue5.826.277.1287
Pretty Stable
Capex To Depreciation0.220.231.6303
Slightly volatile
Payables Turnover0.981.033.3873
Slightly volatile
Sales General And Administrative To Revenue17.2316.4520.9885
Slightly volatile
Research And Ddevelopement To Revenue25.9948.5633.0562
Slightly volatile
Capex To Revenue0.130.11711.133
Pretty Stable
Days Payables Outstanding4444671.4 K
Pretty Stable
Income Quality0.580.750.761
Pretty Stable
Current Ratio6.56.378.3983
Pretty Stable
Receivables Turnover0.971.023.4712
Slightly volatile
Capex Per Share0.00180.00190.8347
Slightly volatile
Average Receivables106.4 K167.1 K144.3 K
Slightly volatile
Revenue Per Share0.01570.01651.1156
Slightly volatile
Interest Debt Per Share0.03490.036811.2799
Slightly volatile
Debt To Assets0.01710.0180.2622
Slightly volatile
Days Of Payables Outstanding4444671.4 K
Pretty Stable
Ebt Per Ebit1.171.071.0733
Pretty Stable
Long Term Debt To Capitalization0.250.380.3087
Slightly volatile
Quick Ratio6.526.378.4235
Pretty Stable
Net Income Per E B T1.11.131.001
Slightly volatile
Cash Ratio4.343.455.5653
Pretty Stable
Days Of Sales Outstanding390372247
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.0393
Slightly volatile
Fixed Asset Turnover0.360.381.4764
Slightly volatile
Debt Ratio0.01710.0180.2622
Slightly volatile
Price Sales Ratio204272263
Pretty Stable
Asset Turnover0.00770.00810.0763
Slightly volatile

Cardiff Oncology Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap66.7 M70.2 M121.6 M
Slightly volatile

Cardiff Fundamental Market Drivers

Cardiff Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cardiff Oncology Financial Statements

Cardiff Oncology stakeholders use historical fundamental indicators, such as Cardiff Oncology's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cardiff Oncology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cardiff Oncology's assets and liabilities are reflected in the revenues and expenses on Cardiff Oncology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cardiff Oncology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue5.2 M5.5 M
Total Revenue785.5 K430.8 K
Cost Of Revenue464.6 K441.4 K
Stock Based Compensation To Revenue 6.27  5.82 
Sales General And Administrative To Revenue 16.45  17.23 
Research And Ddevelopement To Revenue 48.56  25.99 
Capex To Revenue 0.12  0.13 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(81.92)(86.01)

Currently Active Assets on Macroaxis

WDWalker Dunlop
GMGeneral Motors
GMGeneral Motors
BACBank of America
SSentinelOne
When determining whether Cardiff Oncology is a strong investment it is important to analyze Cardiff Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiff Oncology's future performance. For an informed investment choice regarding Cardiff Stock, refer to the following important reports:
How To Invest In Cardiff
Details
Is Cardiff Stock a good investment?
Details
What is Cardiff Oncology's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Cardiff Oncology Correlation against competitors.
For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Can Biotechnology industry sustain growth momentum? Does Cardiff have expansion opportunities? Factors like these will boost the valuation of Cardiff Oncology. Projected growth potential of Cardiff fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Cardiff Oncology demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share
(0.79)
Revenue Per Share
0.008
Quarterly Revenue Growth
(0.27)
Return On Assets
(0.53)
Return On Equity
(1.03)
Understanding Cardiff Oncology requires distinguishing between market price and book value, where the latter reflects Cardiff's accounting equity. The concept of intrinsic value—what Cardiff Oncology's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Cardiff Oncology's price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Cardiff Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardiff Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cardiff Oncology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY